Filing Flows › Comparisons › KYMR vs GLUE
Kymera Therapeutics vs Monte Rosa Therapeutics: KYMR and GLUE compared
Kymera Therapeutics is the larger company: $65.0M of revenue in its latest quarter (Q2 2026) against $54.4M for Monte Rosa Therapeutics (Q3 2026). Kymera Therapeutics is growing faster (+466% against +326% a year earlier). Monte Rosa Therapeutics is more profitable, with an operating margin of -3.6% against -116.3%.
Where the money goes: KYMR and GLUE
Kymera Therapeutics (KYMR) · Q2 2026
Kymera Therapeutics, Q2 2026: revenue $65.0M (+466% year over year), operating margin -116.3%, net loss $61.2M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.
Monte Rosa Therapeutics (GLUE) · Q3 2026
Monte Rosa Therapeutics, Q3 2026: revenue $54.4M (+326% year over year), operating margin -3.6%, net earnings $3.1M, operating cash flow −$41.0M. The chart follows the revenue to costs, profit and cash.
| Kymera Therapeutics (KYMR) | Monte Rosa Therapeutics (GLUE) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $65.0M | $54.4M |
| Revenue growth, Y/Y | +466% | +326% |
| Operating margin | -116.3% | -3.6% |
| Net earnings | −$61.2M | $3.1M |
| Net margin | -94.2% | 5.6% |
| Operating cash flow | −$54.1M | −$41.0M |
Questions
Which is bigger, Kymera Therapeutics or Monte Rosa Therapeutics?
Kymera Therapeutics is the larger company: $65.0M of revenue in its latest quarter (Q2 2026) against $54.4M for Monte Rosa Therapeutics (Q3 2026).
Is Kymera Therapeutics or Monte Rosa Therapeutics growing faster?
Kymera Therapeutics is growing faster (+466% against +326% a year earlier).
Which is more profitable, Kymera Therapeutics or Monte Rosa Therapeutics?
Monte Rosa Therapeutics is more profitable, with an operating margin of -3.6% against -116.3%.
More: Kymera Therapeutics earnings · how Kymera Therapeutics makes money · Monte Rosa Therapeutics earnings · how Monte Rosa Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 5, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.